India Pharma Outlook Team | Tuesday, 09 September 2025
Sanjivani Paranteral Limited's subsidiary, SPL Infusion Pvt. Ltd., has initiated commercial production at its newly established IV Fluid Infusion Plant located in Pune, Maharashtra, effective from 6th September 2025, following the acquisition of the necessary manufacturing license from the relevant authorities.
The Pune site holds strategic significance, providing close proximity to prominent pharmaceutical clusters and hospitals, bolstered by strong infrastructure and supply-chain connectivity, which enables the company to effectively serve both domestic and international markets.
The facility has been designed with a dual emphasis on efficiency and sustainability. It is equipped with cutting-edge plant and machinery that incorporates the latest technology, anticipated to enhance product quality and improve consistency. Furthermore, the installation of solar panels will contribute to an eco-friendly electricity supply, reduce electricity consumption, and lower long-term operational costs.
Also Read: Akums Expands Access to Eurasian Pharma Markets
This advancement represents a crucial milestone in the company's growth trajectory, as it increases manufacturing capacity, establishes a new revenue stream, and further solidifies its position within the healthcare and pharmaceutical manufacturing industry.
Sanjivani Paranteral Ltd. is a prominent and reputable pharmaceutical company committed to providing high-quality, effective, and dependable medicines to its esteemed customers. The company is dedicated to innovation, excellence, and the advancement of healthcare, ensuring the well-being of communities across the globe.
